FindTrial
Sign In

Clinical protocol for comprehensive evaluation of clopidogrel based on real-world patient data

Clinical protocol for comprehensive evaluation of clopidogrel based on real-world patient data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078112
Enrollment
Unknown
Registered
2023-11-29
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Brand clopidogrel Group:None
Generic clopidogrel Group:None

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: Patients with acute myocardial infarction were treated with emergency or elective PCI. Postoperative aspirin combined with clopidogrel dual antiplatelet therapy; Age =18 years old.

Exclusion criteria

Exclusion criteria: Complicated with ischemic stroke, hemorrhagic stroke and peripheral vascular disease; Anticoagulant drugs including warfarin, dabigatran, rivaroxaban, etc.; Severe liver and kidney insufficiency; Coagulation dysfunction; Platelet count > 450×10^9/L or < 100×10^9/L; Pregnant or nursing woman.

Design outcomes

Primary

MeasureTime frame
MACE;Major bleeding event;—

Secondary

MeasureTime frame
Minor bleeding event;Non-bleeding adverse reaction;—

Countries

China

Contacts

Public ContactYangxian

Nanjing Drum Tower Hospital

yangxian-gp4@163.com+86 138 5183 9850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026